Ronald de Wit MD, PhD
Pembrolizumab (Keytruda) demonstrated durable activity in patients with high-risk nonmuscle–invasive bladder cancer (NMIBC) who were resistant to Bacillus Calmette-Guérin (BCG), according to an interim analysis from the single-arm, open-label, phase II KEYNOTE-057 trial.
at the 2018 ESMO Congress, de Wit discussed the clinical implications of pembrolizumab in this NMIBC patient population.
OncLive: Please provide an overview of the KEYNOTE-057 trial.
: I presented the interim results of an ongoing study testing the efficacy and duration of response of pembrolizumab in patients with NMIBC at high risk for disease progression and who were unresponsive to BCG therapy. The data I presented were from cohort A, which was a high-risk population. We had a data cut-off of April 1, 2018, to ensure a sufficient follow-up time for this interim analysis. At that time, we had enrolled 103 patients, and I presented on these patients.
... to read the full story